We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
-4.81%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$503M
AUM Growth
-$106M
Cap. Flow
-$105M
Cap. Flow %
-20.89%
Top 10 Hldgs %
93.44%
Holding
25
New
3
Increased
5
Reduced
11
Closed
1

Top Buys

Rank Stock Value
1
BIOL
Biolase, Inc.
BIOL
+$7.05M
2
SLNO
Soleno Therapeutics
SLNO
+$4.59M
3
ADAP
Adaptimmune Therapeutics
ADAP
+$2.56M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$2.17M
5
ELGX
Endologix Inc
ELGX
+$1.92M

Top Sells

Rank Stock Value
1
MZOR
Mazor Robotics Ltd.
MZOR
+$52.2M
2
TSRO
TESARO, Inc.
TSRO
+$13.7M
3
AXDX
Accelerate Diagnostics
AXDX
+$2.09M
4
QDEL icon
QuidelOrtho
QDEL
+$1.51M
5
PACB icon
Pacific Biosciences
PACB
+$816K

Sector Composition

Rank Sector Weight
1 Healthcare 85.67%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXDX
1
DELISTED
Accelerate Diagnostics
AXDX
$121M 24.04%
461,734
-8,930
-2% -$2.09M
QDEL icon
2
QuidelOrtho
QDEL
$1.21B
$104M 20.57%
2,388,548
-36,868
-2% -$1.51M
TSRO
3
DELISTED
TESARO, Inc.
TSRO
$73.7M 14.64%
891,242
-139,583
-14% -$13.7M
MZOR
4
DELISTED
Mazor Robotics Ltd.
MZOR
$66.7M 13.25%
1,292,776
-927,024
-42% -$52.2M
AMRN
5
Amarin Corp
AMRN
$297M
$25.3M 5.02%
315,165
– –
PACB icon
6
Pacific Biosciences
PACB
$441M
$22.3M 4.43%
8,453,375
-233,080
-3% -$816K
VRML
7
DELISTED
Vermillion, Inc.
VRML
$19M 3.77%
9,825,289
– –
OPK icon
8
Opko Health
OPK
$978M
$18.8M 3.73%
3,826,760
+190,000
+5% +$1.1M
BIOL
9
DELISTED
Biolase, Inc.
BIOL
$13.2M 2.61%
2,469
+1,003
+68% +$7.05M
ADAP
10
DELISTED
Adaptimmune Therapeutics
ADAP
$6.9M 1.37%
1,032,721
+330,860
+47% +$2.56M
AGEN
11
Agenus
AGEN
$326M
$5.04M 1%
78,840
-2,547
-3% -$194K
ARNA
12
DELISTED
Arena Pharmaceuticals Inc
ARNA
$4.78M 0.95%
140,666
+76,293
+119% +$2.17M
EPZM
13
DELISTED
Epizyme, Inc
EPZM
$4.55M 0.9%
362,892
-6,511
-2% -$94.6K
SLNO
14
DELISTED
Soleno Therapeutics
SLNO
$4.3M 0.85%
+159,204
New +$4.59M
CFRX
15
DELISTED
ContraFect Corporation
CFRX
$2.93M 0.58%
3,626
+898
+33% +$742K
AXDX
16
CALL
DELISTED
Accelerate Diagnostics
AXDX
$2.53M 0.5%
27,500
-18,380
-40% -$4.31M
PGEN icon
17
Precigen
PGEN
$2.36B
$2.25M 0.45%
195,000
– –
BIIB icon
18
Biogen
BIIB
$29.8B
$2.03M 0.4%
6,368
– –
ELGX
19
DELISTED
Endologix Inc
ELGX
$1.94M 0.39%
+36,273
New +$1.92M
ARAY icon
20
Accuray
ARAY
$32.2M
$1.62M 0.32%
376,799
-96,457
-20% -$443K
QDEL icon
21
CALL
QuidelOrtho
QDEL
$1.21B
$729K 0.14%
+104,800
New +$4.28M
TSRO
22
CALL
DELISTED
TESARO, Inc.
TSRO
$211K 0.04%
65,000
-35,000
-35% -$3.43M
VANI icon
23
Vivani Medical
VANI
$115M
$97K 0.02%
2,117
– –
NXTM
24
CALL
DELISTED
NxStage Medical Inc.
NXTM
$4K ﹤0.01%
142,800
-1,926,000
-93% -$50.7M
AQB icon
25
AquaBounty Technologies
AQB
$4.73M
– –
-610
Closed -$87K

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q4 2017 Portfolio in Review

As of Q4 2017, Oracle Investment Management held 25 positions worth $503M, down 17% from $610M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Oracle Investment Management withdrew a net $105M in Q4 2017, closing 1 position and reducing 11 holdings. Its most notable exit was AquaBounty Technologies, an estimated $87K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 82% a quarter earlier, followed by Consumer Staples.

Against the trend, Oracle Investment Management opened a new position in Soleno Therapeutics worth $4.3M.

  • Oracle Investment Management's largest Q4 2017 buy was Soleno Therapeutics: 159,204 shares worth $4.3M.
  • Oracle Investment Management added most to Biolase, Inc. in Q4 2017, an estimated $7.05M increase.
  • Oracle Investment Management's biggest Q4 2017 reduction was Mazor Robotics Ltd., cutting an estimated $52.2M.
  • Oracle Investment Management fully exited AquaBounty Technologies in Q4 2017, selling an estimated $87K.
  • Oracle Investment Management's ten largest holdings make up 93% of its $503M portfolio in Q4 2017.
  • Oracle Investment Management opened 3 new positions and closed 1 in Q4 2017.
  • Oracle Investment Management's portfolio value fell 17% quarter-over-quarter to $503M.

Based on Oracle Investment Management's 13F filing for Q4 2017, filed 14 Feb 2018.